WAIT FOR SUGGESTIONS BY CATEGORY OR CONTINUE TYPING IN YOUR KEYWORDS
ENTER ONE OR MULTIPLE KEYWORDS & PRESS THE SEARCH BUTTON
Search
Favorites
Favorites
AdvancedMinimize
Clear
Radical cystectomy against intra-vesical BCG immunotherapy for high risk non-muscle invasive bladder cancer: Results from the randomised controlled BRAVO-feasibility study
BAUS ePoster online library. Catto J. 11/10/20; 304209; P12-6
Disclosure(s): JWFC has received reimbursement for consultancy from Astra Zeneca, Roche and Janssen, speaker fees from BMS, MSD, Nucleix and Roche, and honoraria for membership of advisory boards for Ferring, Roche and Janssen.
Radical cystectomy against intra-vesical BCG immunotherapy for high risk non-muscle invasive bladder cancer: Results from the randomised controlled BRAVO-feasibility study
Catto J1, Gordon K2, Poad H2, Twiddy M3, Johnson M4, Jain S5, Chalal R6, Simms M7, Dooldeniya M8, Bell R9, Koenig P10, Conroy S1, Goodwin L1, Noon A1, Croft J2, Collinson M2, Brown J2 1Sheffield Teaching Hospitals Nhs Trust, United Kingdom, 2Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom, 3Institute of Clinical and Applied Health Research, University of Hull, UK, 4Freeman Hospital, Newcastle, UK, 5St James's University Hospital, Leeds, UK, 6Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK, 7Hull and East Yorkshire NHS Trust, UK, 8Mid Yorkshire Hospitals NHS Trust, Wakefield, UK, 9Churchill Hospital, Oxford University Hospitals NHS Trust, Uk, 10Airedale NHS Foundation Trust, Keighley, UK
Purpose: High-risk non-muscle invasive bladder cancer (NMIBC) is a heterogeneous disease. Treatments include maintenance BCG (mBCG) and Radical Cystectomy (RC).
Methods: We conducted a prospective multicentre RCT to determine the feasibility of a phase 3 trial comparing BCG with RC in BCG naïve patients. Eligible participants had new high-risk NMIBC suitable for both treatments. The primary outcome was recruited patients.
Results: Between October 2016 and March 2018, we approached 185 eligible patients and recruited 51 (27.5%). Of these, 1 withdrew and 25 were randomised to each of mBCG and RC. In the mBCG arm, 23/25 (92%) patient received mBCG, 4 had NMIBC at 6 weeks, 3 with NMIBC at 4 months and 4 received RC. At closure, 1 patient had metastatic BC. In the RC arm, 20 (80%) participants received surgery, including 5 (25%) with no tumour, 13 (65%) with high grade NMIBC (65%) and 2 (10%) with muscle invasion in their specimen. At closure, all patients were free of disease. Adverse events were common, mostly mild and equally distributed (13/20 (65.0%) with RC and 15/23 (65.2%) with mBCG). The quality of life of both arms was broadly similar by 12 months.
Conclusion: An RCT comparing mBCG and RC, using survival as an endpoint, will be challenging to recruit into. Patients will agree to be randomised if clinicians are in equipoise. Around 10% of patients with high risk NMIBC have a lethal disease and may be better treated by primary radical treatment.
Radical cystectomy against intra-vesical BCG immunotherapy for high risk non-muscle invasive bladder cancer: Results from the randomised controlled BRAVO-feasibility study
Catto J1, Gordon K2, Poad H2, Twiddy M3, Johnson M4, Jain S5, Chalal R6, Simms M7, Dooldeniya M8, Bell R9, Koenig P10, Conroy S1, Goodwin L1, Noon A1, Croft J2, Collinson M2, Brown J2 1Sheffield Teaching Hospitals Nhs Trust, United Kingdom, 2Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom, 3Institute of Clinical and Applied Health Research, University of Hull, UK, 4Freeman Hospital, Newcastle, UK, 5St James's University Hospital, Leeds, UK, 6Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK, 7Hull and East Yorkshire NHS Trust, UK, 8Mid Yorkshire Hospitals NHS Trust, Wakefield, UK, 9Churchill Hospital, Oxford University Hospitals NHS Trust, Uk, 10Airedale NHS Foundation Trust, Keighley, UK
Purpose: High-risk non-muscle invasive bladder cancer (NMIBC) is a heterogeneous disease. Treatments include maintenance BCG (mBCG) and Radical Cystectomy (RC).
Methods: We conducted a prospective multicentre RCT to determine the feasibility of a phase 3 trial comparing BCG with RC in BCG naïve patients. Eligible participants had new high-risk NMIBC suitable for both treatments. The primary outcome was recruited patients.
Results: Between October 2016 and March 2018, we approached 185 eligible patients and recruited 51 (27.5%). Of these, 1 withdrew and 25 were randomised to each of mBCG and RC. In the mBCG arm, 23/25 (92%) patient received mBCG, 4 had NMIBC at 6 weeks, 3 with NMIBC at 4 months and 4 received RC. At closure, 1 patient had metastatic BC. In the RC arm, 20 (80%) participants received surgery, including 5 (25%) with no tumour, 13 (65%) with high grade NMIBC (65%) and 2 (10%) with muscle invasion in their specimen. At closure, all patients were free of disease. Adverse events were common, mostly mild and equally distributed (13/20 (65.0%) with RC and 15/23 (65.2%) with mBCG). The quality of life of both arms was broadly similar by 12 months.
Conclusion: An RCT comparing mBCG and RC, using survival as an endpoint, will be challenging to recruit into. Patients will agree to be randomised if clinicians are in equipoise. Around 10% of patients with high risk NMIBC have a lethal disease and may be better treated by primary radical treatment.
By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS). USER TERMS AND CONDITIONS | PRIVACY POLICY
Cookie Settings Accept Terms & all Cookies
Anonymous User Privacy Preferences
Strictly Necessary Cookies (Always Active)
MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.
Performance Cookies
Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.